Hematologic Oncology

The panel reviews therapeutic options for managing transplant-associated thrombotic microangiopathy and the challenges associated with currently existing agents.

Unmet needs and current areas that are being studied in in essential thrombocythemia.

Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea. 

Naval G. Daver, MD, leads the discussion on the use sorafenib in combination with hypomethylating agents (HMA) for the treatment of relapsed FLT3-mutated AML.

Examining the need to achieve a true CR (complete remission), especially with recent targeted therapies in relapsed/refractory acute myeloid leukemia.

Experts in hematology-oncology share insights on approaching initial treatment and the treatment goals for acute and chronic GVHD.

Experts in hematology-oncology build a discussion on differences in patient presentation and diagnosis of different types of indolent non-Hodgkin lymphomas such as marginal zone lymphoma and follicular lymphoma.

A discussion on the role of prophylactic therapy for patients after transplant as well as available options for GVHD prophylaxis.

Lori A. Leslie, MD, and Anthony Mato, MD, MSCE, discuss the epidemiology, etiology, and risk factors for different types of lymphoma and provide key insights into those classified as indolent non-Hodgkin’s lymphoma.

William Gradishar, MD, discusses the efficacy of pretreatment with intravenous cetirizine in the prevention of infusion reactions in patients with breast cancer and other malignancies.

Health Canada has approved daratumumab injection, a subcutaneous formulation of daratumumab, for use in combination with bortezomib, cyclophosphamide, and dexamethasone in the treatment of patients with newly diagnosed light chain amyloidosis.

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

Factors that should be considered when evaluating patients with relapsed/refractory follicular lymphoma for CAR T-cell therapy.

Experts in the field of hematopoietic stem cell transplantation provide their views and experiences with various interventions for managing transplant-associated thrombotic microangiopathy.

Jeffrey Laurence, MD, reviews the available interventions used to mitigate or treat transplant-associated thrombotic microangiopathy.

Expert discusses risk-stratification models, prognosis, and the management of complications in essential thrombocythemia.

Naval G. Daver, MD, reviews the safety and efficacy of quizartinib in relapsed/refractory acute myeloid leukemia as seen in the phase 3 QuANTUM-R study.

Key opinion leaders discuss the current unmet needs in myelofibrosis and ongoing approaches to look forward to in hopefully overcoming these challenges.

Experts in leukemia comment on the utilization of FLT3 inhibitors in combination with chemotherapy in early and recurrent acute myeloid leukemia.

AFM13, an innate cell engager, demonstrated an objective response rate of 100% in adult patients with CD30-positive, relapsed/refractory Hodgkin lymphoma.

Hematologist-oncologists review the typical presentation and diagnosis of acute and chronic GVHD and define how severity is classified.

Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, provide insight on the nature of graft-vs-host disease (GVHD) and common risk factors for acute and chronic GVHD.

Dr. Fowler discusses the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, the implications of the regulatory decision on clinical practice, and potential next steps for the PI3Kδ and CK1ε inhibitor.

Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.

The combination of the selective MCL-1 inhibitor AMG 176 plus gilteritinib was found to synergistically target preclinical models of FLT3 internal tandem duplication–mutated acute myeloid leukemia.